cyc 202 has been researched along with Osteogenic Sarcoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fanelli, M; Hattinger, CM; Koster, J; Picci, P; Serra, M; Tavanti, E; Vella, S; Versteeg, R | 1 |
| Hernández, G; Santamariña, M; Zalvide, J | 1 |
| Al-Omran, M; de Nigris, F; Giordano, A; Infante, T; Mancini, FP; Minucci, PB; Napoli, C; Schiano, C; Zullo, A | 1 |
| Bach, S; Filipski, E; Gianella-Borradori, A; Iacobelli, S; Iurisci, I; Lévi, F; Meijer, L; Reinhardt, J | 1 |
| Lian, JB; Mujeeb, KA; Rajgopal, A; Stein, GS; Stein, JL; van Wijnen, AJ; Young, DW | 1 |
| Horky, M; Kotala, V; Strnad, M; Trbusek, M; Uldrijan, S; Vojtesek, B | 1 |
6 other study(ies) available for cyc 202 and Osteogenic Sarcoma
| Article | Year |
|---|---|
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; DNA Damage; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Molecular Targeted Therapy; Osteosarcoma; Purines; Roscovitine | 2016 |
CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Down-Regulation; Humans; Osteosarcoma; Protein Kinase Inhibitors; Purines; Retinoblastoma Protein; RNA Interference; Roscovitine | 2008 |
Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis.
Topics: Animals; Antineoplastic Agents; Aorta; Apoptosis; Bone Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Osteosarcoma; Purines; Roscovitine; Up-Regulation; YY1 Transcription Factor | 2013 |
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Circadian Rhythm; Gene Expression; Male; Mice; Osteosarcoma; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic | 2006 |
Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells.
Topics: Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Cyclin B; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Humans; Immunoprecipitation; Mitosis; Mutagenesis, Site-Directed; Okadaic Acid; Osteoblasts; Osteosarcoma; Phosphoprotein Phosphatases; Phosphorylation; Protein Binding; Purines; Roscovitine; Transfection | 2007 |
Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Melanoma; Mice; Osteosarcoma; Purines; Recombinant Proteins; Roscovitine; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |